142-78-9

Usage

Definition

ChEBI: An N-(long-chain-acyl)ethanolamine resulting from the formal condensation of the carboxy group of dodecanoic acid (myristic acid) with the amino group of ethanolamine.

General Description

Cream-colored flakes.

Air & Water Reactions

Insoluble in water.

Reactivity Profile

LAURIC ACID MONOETHANOLAMIDE is a very weak base. Reacts with azo and diazo compounds to generate toxic gases. Flammable gases are formed with strong reducing agents. Reacts with dehydrating agents such as P2O5 or SOCl2. Combustion generates mixed oxides of nitrogen.

Fire Hazard

Flash point data for LAURIC ACID MONOETHANOLAMIDE are not available, but LAURIC ACID MONOETHANOLAMIDE is probably combustible.

Flammability and Explosibility

Notclassified

InChI:InChI=1/C12H25NO.C2H7NS/c1-2-3-4-5-6-7-8-9-10-11-12(13)14;3-1-2-4/h2-11H2,1H3,(H2,13,14);4H,1-3H2

Upstream product

• 143-07-7 lauric acid 
• 141-43-5 ethanolamine 
• 111-82-0 methyl n-dodecanoate 
• 106-33-2 ethyl laurate 
• 112-16-3 n-dodecanoyl chloride 
• 56895-81-9 C₁₄H₂₆O₄ 

Downstream Products

• 10431-84-2 2-Undecyl-Δ²-oxazolin 
• 7596-88-5 N-dodecanoylglycine 
• 14246-55-0 N-myristoylglycine 
• 2441-41-0 N-palmitoyl glycine 
• 6333-54-6 N-stearoylglycine 
• 14305-32-9 N-n-decanoylglycine 
• 14246-53-8 N-(1-oxooctyl)glycine 
• 14037-25-3 2-(1-phenylcarbamoyl-undecylidene)-oxazolidine-3-carboxylic acid anilide 
• 80829-06-7 2-(lauramido)ethyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate 

Relevant academic research and scientific papers

Development and preclinical evaluation of new inhaled lipoglycopeptides for the treatment of persistent pulmonary methicillin-resistant staphylococcus aureus infections

Chronic pulmonary methicillin-resistant Staphylococcus aureus (MRSA) disease in cystic fibrosis (CF) has a high probability of recurrence following treatment with standard-of-care antibiotics and represents an area of unmet need associated with reduced life expectancy. We developed a lipoglycopeptide therapy customized for pulmonary delivery that not only demonstrates potent activity against planktonic MRSA, but also against protected colonies of MRSA in biofilms and within cells, the latter of which have been linked to clinical antibiotic failure. A library of next-generation potent lipoglycopeptides was synthesized with an emphasis on attaining superior pharmacokinetics (PK) and pharmacodynamics to similar compounds of their class. Our strategy focused on hydrophobic modification of vancomycin, where ester and amide functionality were included with carbonyl configuration and alkyl length as key variables. Candidates representative of each carbonyl attachment chemistry demonstrated potent activity in vitro, with several compounds being 30 to 60 times more potent than vancomycin. Selected compounds were advanced into in vivo nose-only inhalation PK evaluations in rats, where RV94, a potent lipoglycopeptide that utilizes an inverted amide linker to attach a 10-carbon chain to vancomycin, demonstrated the most favorable lung residence time after inhalation. Further in vitro evaluation of RV94 showed superior activity to vancomycin against an expanded panel of Gram-positive organisms, cellular accumulation and efficacy against intracellular MRSA, and MRSA biofilm killing. Moreover, in vivo efficacy of inhaled nebulized RV94 in a 48 h acute model of pulmonary MRSA (USA300) infection in neutropenic rats demonstrated statistically significant antibacterial activity that was superior to inhaled vancomycin.

LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF

The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC. The bacterial infection can comprise intracellular bacteria, planktonic bacteria, bacteria present in a biofilm, or a combination thereof.

Synthesis of: N-acyl amide natural products using a versatile adenylating biocatalyst

Natural products are secondary metabolites produced by many different organisms such as bacteria, fungi and plants. These biologically active molecules have been widely exploited for clinical application. Here we investigate TamA, a key enzyme from the biosynthetic pathway of tambjamine YP1, an acylated bipyrrole that is produced by the marine microorganism Pseudoalteromonas tunicata. TamA is a didomain enzyme composed of a catalytic adenylation (ANL) and an acyl carrier protein (ACP) domain that together control the fatty acid chain length of the YP1. Here we show that the TamA ANL domain alone can be used to generate a range of acyl adenylates that can be captured by a number of amines thus leading to the production of a series of fatty N-acyl amides. We exploit this biocatalytic promiscuity to produce the recently discovered class of N-acyl histidine amide natural products from Legionella pneumophila.

A catalyst-free, waste-less ethanol-based solvothermal synthesis of amides

A green, one-pot approach based on the solvothermal amidation of carboxylic acids with amines has been developed for the synthesis of diverse aliphatic and aromatic amides. It does not require the use of catalysts or coupling reagents and it occurs in the presence of ethanol that has been proved to have a key role in the process. The proposed strategy is also extendable to biologically active amides and could represent a low-cost and waste-less alternative to the common synthetic pathways.

Design, synthesis and CoMFA studies of OEA derivatives as FAAH inhibitors

A total of 26 novel oleoylethanolamide derivatives were designed, synthesized, and characterized. All synthesized targets compounds were screened for their inhibitory activities against fatty acid amide hydrolase. Among of them, 13 compounds inhibit fatty acid amide hydrolase by 50% at the concentration of 100 μM. Of these compounds, the most active one is compound 9, which inhibit fatty acid amide hydrolase activity 98.35% at the concentration of 100 μM. Comparative molecular field analysis analyzes were performed based on obtained biological activities data and resulted in a statistically reliable comparative molecular field analysis model with high predictive abilities (r2 = 0.978, q2 = 0.613).

Fatty acid monoethanol amide succinate sulfonate and its preparation method and application

The invention provides a preparation method for fatty acid monoethanolamide succinate sulfonate. The preparation method is characterized by comprising the steps of generating amidation reaction by fatty acid and monoethanolamide to generate fatty acid monoethanolamide which is reacted with butenedioic acid or maleic anhydride to generate fatty acid monoethanolamide butenedioic acid ester, and generating salt formation reaction of the fatty acid monoethanolamide butenedioic acid ester and hydrosulphite to generate the fatty acid monoethanolamide succinate sulfonate. Compared with the prior art, trace cutting liquid prepared from the fatty acid monoethanolamide succinate sulfonate provided by the invention has high lubricating property, extreme pressure antiwear property and biological degradability; a high-end requirement on metal processing can be met only by using an extremely small amount of the trace cutting liquid; therefore, harm to the environment and workers is alleviated, and the pollution to the environment is reduced to the maximum extent.

IMPROVED PROCESS FOR ALAKNOLAMIDE SYNTHESIS

The present invention is directed to a process of making alkanolamides wherein the "aging" time is reduced and the diethanol amide to ester ratio in the finished product is increased. Further provided is an additive composition comprising an alkanolamide which contains a reduced amount of DEA and BHEP.

Pharmaceuticals and Surfactants from Alga-Derived Feedstock: Amidation of Fatty Acids and Their Derivatives with Amino Alcohols

Amidation of renewable feedstocks, such as fatty acids, esters, and Chlorella alga based biodiesel, was demonstrated with zeolites and mesoporous materials as catalysts and ethanolamine, alaninol, and leucinol. The last two can be derived from amino acids present in alga. The main products were fatty alkanol amides and the corresponding ester amines, as confirmed by NMR and IR spectroscopy. Thermal amidation of technical-grade oleic acid and stearic acid at 180°C with ethanolamine were non-negligible; both gave 61% conversion. In the amidation of stearic acid with ethanolamine, the conversion over H-Beta-150 was 80% after 3 h, whereas only 63% conversion was achieved for oleic acid; this shows that a microporous catalyst is not suitable for this acid and exhibits a wrinkled conformation. The highest selectivity to stearoyl ethanolamide of 92% was achieved with mildly acidic H-MCM-41 at 70% conversion in 3 h at 180°C. Highly acidic catalysts favored the formation of the ester amine, whereas the amide was obtained with a catalyst that exhibited an optimum acidity. The conversion levels achieved with different fatty acids in the range C12-C18 were similar; this shows that the fatty acid length does not affect the amidation rate. The amidation of methyl palmitate and biodiesel gave low conversions over an acidic catalyst, which suggested that the reaction mechanism in the amidation of esters was different. Pores versus acidity: The structures and properties of zeolites and mesoporous materials are investigated as catalysts for the amidation of renewable feedstocks, such as fatty acids, esters, and Chlorella alga based biodiesel, with ethanolamine, alaninol, and leucinol as nitrogen sources.

Alkyl sulfonyl derivatized PAMAM-G2 dendrimers as nonviral gene delivery vectors with improved transfection efficiencies

Amphiphilic dendrimer-based gene delivery vectors bearing peripheral alkyl sulfonyl hydrophobic tails were constructed using low-generation PAMAM-G2 as the core and functionalized by means of the aza-Michael type addition of its primary amino groups to vinylsulfone derivatives as an efficient tool for surface engineering. While the unmodified PAMAM-G2 was unable to efficiently transfect eukaryotic cells, functionalized PAMAM-G2 dendrimers were able to bind DNA at low N/P ratios, protect DNA from digestion with DNase I and showed high transfection efficiencies and low cytotoxicity. Dendrimers with a C18 alkyl chain produced transfection efficiencies up to 3.1 fold higher than LipofectAMINE 2000 in CHO-k1 cells. The dendriplexes based in functionalized PAMAM-G2 also showed the ability to retain their transfection properties in the presence of serum and the ability to transfect different eukaryotic cell lines such as Neuro-2A and RAW 264.7. Taking advantage of the vinylsulfone chemistry, fluorescent PAMAM-G2 derivatives of these vectors were prepared as molecular probes to determine cellular uptake and internalization through a clathrin-independent mechanism.

Synthesis and biological activity of N-acyl O-indolylalkyl ethanolamines

The plant-growth regulators, indole-3-carboxylic acids, were introduced into N-acyl ethanolamines, and a series of N-acyl O-indolylalkyl ethanolamines were prepared. Their biological activities to regulate rape hypocotyl elongation, cucumber cotyledon expansion and common wheat coleoptile growth were tested. The results indicate that the title compounds inhibited rape hypocotyl elongation, especially the indole-3-propionic acid derivatives, whose bioactivity was better than that of indole-3-acetic acid.